 |
      |
 |
 Roberto C. Arduino, MD Associate Professor of Medicine Department of Medicine Division of Infectious Diseases The University of Texas-Houston Dr. Roberto C. Arduino is currently Associate Professor of Medicine, Division of Infectious Diseases at The University of Texas Health Science Center at Houston, Principal investigator for HART (Houston AIDS Research Team) unit of “The Terry Beirn Community Programs for Clinical Research on AIDS” (CPCRA), Co-Director of Clinical Core for the BCM/UT Center for AIDS Research, and member of Committee for the Protection of Human Subjects at UTHSC-Houston. Dr. Arduino graduated with Diploma of Honors from the Universidad de Buenos Aires, School of Medicine, Buenos Aires, Argentina. During medical school, he joined the Department of Cell Biology, Histology and Embryology as Teaching Assistant. After graduating, he was appointed Assistant Professor in Cell Biology and Histology. He completed his residency in Internal Medicine at the Universidad de Buenos Aires, University Hospital “José de San Martín”, including one year as Chief Medical Resident. From 1987 to 1989, he received fellowship training in infectious diseases at the Sanatorio Güemes, where he was actively involved in conducting clinical trials. In December 1990, Dr. Arduino joined the Infectious Diseases Fellowship at the Division of Infectious Diseases of the Department of Internal Medicine at The University of Texas Health Science Center at Houston. During his fellowship, Dr. Arduino explored the interaction between enterococci and the human host defense system under the guidance of Drs. Barbara E. Murray and Robert M. Rakita, and worked at Thomas Street Clinic providing care for patients living with HIV. |
In April 1995, Dr. Arduino returned to Buenos Aires to work at
the Fundación del Centro de Estudios Infectológicos
as director of clinical research. In addition, he was responsible
for the organization of a clinical virology laboratory and pulse-field
gel electrophoresis. While in Argentina from 1995 to 1997,
Dr. Arduino collaborated in the design and establishment of Helios
Salud, a clinic for the treatment of patients with HIV infection. |
Marvin Belzer, MD Marvin Belzer MD is an Associate Professor of Clinical Pediatrics and Medicine at the USC Keck School of Medicine. He graduated from medical school at USC in 1986. He completed his internship and residency at UC Irvine in Primary Care Internal Medicine. From there came to CHLA in 1989 and completed his fellowship in Adolescent Medicine in 1991. Since 1991 Dr. Belzer has been the Medical Director of the Risk Reduction Program and became Clinical Director of the Teenage Health Center in 1995. Dr. Belzer has one of the largest adolescent HIV clinics in the West. He has developed a large clinical research program that is engaged in large multi-site clinical trials for youth infected with HIV. |
Current
research network affiliations include the Adolescent HIV/AIDS Trails
Network, Pediatric AIDS Clinical Trials Group and the CDC Project
Legacy. Dr. Belzer has been involved in multiple studies evaluating
medication adherence He also is involved in HIV prevention studies
for high-risk adolescent populations. These include studies
of high-risk behaviors of male-to-female transgender youth and
well as community mobilization interventions involving young men-who-have-sex-men. |
Tony Mills, MD Medical Director, Anthony Mills MD Inc. Executive Committee and Treasurer, American Academy of HIV Medicine Assistant Professor of Clinical Medicine, David Geffen School of Medicine at UCLA Editorial Advisory Board, Muscle & Fitness Magazine Los Angeles-based physician Tony Mills is a leading clinician in the fields of men’s health and HIV disease. He serves as the primary care provide for 1500 patients including over 600 living with HIV. Dr. Mills received his undergraduate and medical degrees from Duke University. He completed an internship in Internal Medicine, a residency in Anesthesiology and a fellowship in Cardiovascular Anesthesiology, all at the University of California, San Francisco. He is a member in many professional societies including the American Medical Association, the American Academy of HIV Medicine, Infectious Disease Society of America, American Society of Microbiology, and the HIV Medical Association Dr. Mills is actively involved in the HIV community. He serves on the Executive Committee and as the National Treasurer of the American Academy of HIV Medicine. In addition, he sits on the Institutional Review Board of the AIDS Research Alliance and is the Chairman of the IRB at Olympia Medical Center in Los Angeles. |
He
is a nationally recognized speaker on a variety of healthcare issues
including HIV treatment and care, men's health, substance abuse and
addictive disease. He speaks to a wide range of audiences including
physician groups, educational seminars, and community forums. As an Editorial Advisory Board Member at Muscle and Fitness Magazine, Dr. Mills combines his own passion for health and physical fitness with his medical expertise to advise and educate bodybuilders and fitness enthusiasts. Dr Mills is an experienced clinical investigator with extensive research experience. He has been a principal investigator on over 15 trials dealing with many aspects of HIV disease between 2000 and 2005. His office is actively engaged in clinical research with over a dozen clinical trials currently ongoing. Dr. Mills has served as a consultant to many pharmaceutical companies including Merck, GlaxoSmithKline, Abbott, Gilead, Ortho Biotech, Pfizer, Monogram Biosciences, and Bristol-Myers Squibb. He has also worked with government panels at the National Institutes of Health and the Food and Drug Administration. Dr. Mills has been recognized by the San Francisco Board of Supervisors and the California legislature for his outstanding contributions to the community. Presentation Date: November 17, 2006 Crystal Methamphetamine in HIV |
 Haran T. Schlamm, MD Medical Director, Team Leader Worldwide Hospital Anti-infective Team Pfizer Global Pharmaceuticals Graduated Harvard College with a degree in Biochemistry. Began career in clinical research as a research coordinator for a pivotal clinical trial at a major hospital affiliated with Harvard Medical School. Started medical education in French at the Catholic University of Louvain in Brussels, Belgium, and completed MD degree at Mt. Sinai School of Medicine in NYC. Completed residency in internal medicine and specialty in infectious diseases at Beth Israel Medical Center in NY during the early years of the HIV epidemic. Held several academic medical positions in NY including Medical Director of the AIDS Clinic at NYU-Bellevue Hospital. Presented results of independent clinical research at major international conferences and published several papers on clinical management of AIDS patients. |
Started career in clinical drug development
at Pfizer in 1994. Contributed to the clinical development of voriconazole
as a key member of the development team at Pfizer Global Research
and Development. As the Project Physician, developed and conducted
the Global Voriconazole Aspergillosis Treatment study – the
largest comparative study of invasive aspergillosis ever conducted
– which demonstrated that initial treatment with Voriconazole
was superior to the current standard treatment for this condition
in terms of safety, efficacy and survival. Also managed the Global
Voriconazole Candidemia Treatment study – the largest comparative
study of candidemia ever conducted - which demonstrated that initial
treatment with Voriconazole was equivalent to the current standard
treatment for this condition in terms of safety, efficacy and survival,
with reduced nephrotoxicity.
Recently appointed as Medical Director,
Team Leader for the Worldwide Hospital Anti-infective Team at Pfizer
Global Pharmaceuticals group. Leads a multidisciplinary team responsible
for medical development of a portfolio of anti-infectives including
Vfend, Eraxis and Zyvox. |
 David M. Simpson , MD Professor of Neurology, Mount Sinai School of Medicine Director, Clinical Neurophysiology Laboratories Director, Neuro-AIDS Program Mount Sinai Hospital New York, New York David M. Simpson, MD, is currently Professor of Neurology at Mount Sinai School of Medicine in New York, New York. In addition, he is Director of the Clinical Neurophysiology Laboratories and Director of the Neuro-AIDS Program at Mount Sinai Hospital. Dr. Simpson received his medical degree from State University of New York (SUNY) at Buffalo School of Medicine. He completed an internship in Internal Medicine at University Hospitals of Cleveland, Case Western Reserve University in Cleveland, Ohio, and a residency in Neurology at Cornell University Medical Center in New York. He completed a fellowship in Clinical Neurophysiology at Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts. |
Dr.
Simpson is a member of the American Neurological Association and
the American Pain Society. He is a fellow of the American Academy
of Neurology and the American Academy of Neuromuscular and Electrodiagnostic
Medicine. He is on the editorial board of AIDS Patient Care, Neurology
and Clinical Neurophysiology, and Current HIV/AIDS Reports,
and he is an ad-hoc reviewer for Annals of Internal Medicine, Annals
of Neurology, Archives of Internal Medicine, and American
Journal of Medicine, among others. Dr. Simpson has authored
over 250 original papers, book chapters, reviews and abstracts.
Dr. Simpson is the principal investigator for several studies,
including the treatment of neuropathic pain in patients with painful
HIV-associated neuropathy and treatment of spasticity with botulinum
toxin. Presentation Date: February 16, 2007 Neurological Complications of HIV/AIDS |
Prakash Sista, PhD Los Angeles HIV Intercity Rounds Dr. Prakash Sista is Director of Clinical Virology at VircoLab Inc. since January 2006. Prior to joining Virco, Prakash spent 2 years as the Section Head for Viral Validation at Bayer Biological Products, which subsequently became Talecris Biotherapeutics. He led a group that validated specific manufacturing steps, which were claimed for the effective removal of model and medically relevant viruses from donated human plasma. Before going to Bayer Biologicals, Prakash was Asst. Director of Clinical Virology at Trimeris Inc. and was closely involved in the development and subsequent approval of the fusion inhibitor T-20. |
Dr.
Sista earned a Ph.D. in Biology from McGill University in Canada and
also has BS and MS degrees in Microbiology from his native country,
India. In addition to his interest in the area of HIV, he has
worked and published in diverse areas of Biology such as DNA replication
termination, NF-kB family of mammalian transcription factors, development
of cell-based assays to evaluate signal transduction and plant-microbe
symbiosis. Presentation Date: November 3, 2006 Role of Genotyping/Phenotyping When Faced With Resistant Virus |
�2006 AIDS Healthcare Foundation. All Rights Reserved. |